Etanercept improves quality of life outcomes and treatment satisfaction in patients with moderate to severe plaque psoriasis in clinical practice

Journal of Cutaneous Medicine and Surgery

Volumn 16, Issue 6, 2012, Pages 407-416

  Vender, Ron ^a   Lynde, Charles ^a   Gilbert, Martin ^a   Ho, Vincent ^a   Sapra, Sheetal ^a   Poulin Costello, Melanie ^a  

^a not available

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT;

ADULT; ARTICLE; CANADIAN; CLINICAL ASSESSMENT TOOL; CLINICAL EFFECTIVENESS; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; DRUG SAFETY; ETHNIC GROUP; EUROQOL 5D; FEMALE; GENERAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHASE 4 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT SATISFACTION QUESTIONNAIRE FOR MEDICATION; UNSPECIFIED SIDE EFFECT;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PATIENT SATISFACTION; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRES; RECEPTORS, TUMOR NECROSIS FACTOR; TIME FACTORS;

EID: 84872355114     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1177/120347541201600609     Document Type: Article

References (32)

1. de Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc 2004;9:140-7, doi:10.1046/j.1087-0024.2003.09110.x. (Pubitemid 38457272)
2. Kilic A, Gulec MY, Gul U, Gulec H. Temperament and character profile of patients with psoriasis. J Eur Acad Dermatol Venereol 2008;22:537-42, doi:10.1111/j.1468-3083.2007.02460.x. (Pubitemid 351541046)
3. Gelfand JM, Feldman SR, Stern RS, et al. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 2004;51:704-8, doi:10.1016/j.jaad.2004.04.014. (Pubitemid 39516879)
4. Elewski B, Leonardi C, Gottlieb AB, et al. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis. Br J Dermatol 2007;156:138-42, doi:10.1111/j.1365- 2133.2006.07585.x. (Pubitemid 44924157)
5. Feldman SR, Kimball AB, Krueger GG, et al. Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. J Am Acad Dermatol 2005;53:887-9, doi:10.1016/j.jaad.2005.06.053. (Pubitemid 41501389)
6. Gelfand JM, Kimball AB, Mostow EN, et al. Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment. Value Health 2008;11:400-7, doi:10.1111/j.1524-4733.2007.00251.x. (Pubitemid 351712967)
7. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139:1627-32, doi:10.1001/archderm.139.12.1627. (Pubitemid 37523083)
8. Krueger GG, Langley RG, Finlay AY, et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol 2005;153:1192-9, doi:10.1111/j.1365-2133.2005.06948.x. (Pubitemid 41779576)
9. Leonardi C, Strober B, Gottlieb AB, et al. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. J Drugs Dermatol 2010;9:928-37.
10. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22, doi:10.1056/ NEJMoa030409. (Pubitemid 37448924)
11. Moore A, Gordon KB, Kang S, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 2007;56:598-603, doi:10.1016/j.jaad.2006.09.002. (Pubitemid 46400183)
12. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304-12, doi:10.1111/j.1365-2133.2005. 06688.x. (Pubitemid 40933433)
13. Papp KA, Poulin Y, Bissonnette R, et al. Assessment of the longterm safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J Am Acad Dermatol. [Epub 2010 Sep 16]
14. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial Lancet 2006;367:29-35, doi:10.1016/S0140-6736(05)67763-X. (Pubitemid 43038667)
15. Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007;143:719-26, doi:10.1001/archderm.143.6.719. (Pubitemid 46955730)
16. Kirby B, Richards HL, Woo P, et al. Physical and psychologic measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol 2001;45:72-6, doi:10.1067/mjd.2001.114592. (Pubitemid 32655696)
17. Townshend AP, Chen CM, Williams HC. How prominent are patient-reported outcomes in clinical trials of dermatological treatments? Br J Dermatol 2008;159:1152-9.
18. Dauden E, Griffiths CE, Ortonne JP, et al. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol 2009;23:1374-82, doi:10.1111/j.1468-3083.2009.03321. x.
19. Luger TA, Barker J, Lambert J, et al. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2009;23:896-904, doi:10.1111/j.1468- 3083.2009.03211.x.
20. Reich K, Segaert S, Van De KP, et al. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis. Dermatology 2009;219:239-49, doi:10.1159/000237871.
21. Langham S, Langham J, Goertz HP, Ratcliffe M. Large-scale, prospective, observational studies in patients with psoriasis and psoriatic arthritis: a systematic and critical review. BMC Med Res Methodol 2011;11:32, doi:10.1186/1471-2288-11-32.
22. Vender R, Lynde C, Gillbert M, et al. One-year, multicentre, openlabel, single-arm study evaluating real-world safety and effectiveness of etanercept for the treatment ofmoderate-to-severe plaque psoriasis. Submitted to JCMS Feb 17, 2012.
23. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-6, doi:10.1111/j.1365-2230.1994.tb01167.x. (Pubitemid 24194579)
24. Feldman SR, Kimball A, Woolley JM. Clinically meaningful improvements in health-related quality of life from etanercept therapy for patients with moderate to severe psoriasis. J Am Acad Dermatol 2004;50 Suppl 1:P155, doi:10.1016/j.jaad.2003.10.543.
25. Khilji FA, Gonzalez M, Finlay AY. Clinical meaning of change in Dermatology Life Quality Index scores. Br J Dermatol 2002;147 Suppl 62:25-54.
26. Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53-72, doi:10.1016/0168-8510(96)00822-6. (Pubitemid 26191458)
27. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108, doi:10.1097/00005650-199711000-00002. (Pubitemid 127453463)
28. Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004;2:12, doi:10.1186/1477-7525-2-12.
29. Carlin JB, Li N, Greenwood P, Coffey C. Tools for analyzing multiple imputed datasets. Stata J 2003;3:226-44.
30. National Research Council 2010, Panel on Handling Missing Data in Clinical Trials, Committee on National Statistics, Division of Behavioral and Social Sciences and Education. The prevention and treatment of missing data in clinical trials. Washington (DC): The National Academies Press; 2010.
31. Konig HH, Bernert S, Angermeyer MC, et al. Comparison of population health status in six European countries: results of a representative survey using the EQ-5D questionnaire. Med Care 2009;47:255-61, doi:10.1097/MLR. 0b013e318184759e.
32. Driessen RJ, Bisschops LA, Adang EM, et al. The economic impact of high-need psoriasis in daily clinical practice before and after the introduction of biologics. Br J Dermatol 2010;162:1324-9, doi:10.1111/j.1365-2133.2010. 09693.x.